CONMED Corporation stock gains support from solid earnings and guidance

CONMED Corporation stock has recently traded around the mid-40s USD, backed by better than expected quarterly earnings and a full-year 2026 EPS guidance that points to continued profit growth.

CONMED Corporation stock (ISIN US2074101013) is drawing attention in early September 2026 as the medical technology company continues to trade near the mid-40s USD after delivering better than expected quarterly results in its latest reported period and confirming full-year 2026 earnings guidance.

Earnings beat with revenue growth

According to a recent summary of the latest quarterly report, CONMED Corporation reported adjusted earnings per share of 1.38 USD in its most recently reported quarter, which ended in the summer of 2026, beating the average analyst expectation of 1.11 USD EPS for that period.

In the same quarter, the company generated revenue of 343.5 million USD, slightly above the 337.6 million USD that analysts had been expecting for the period and representing a 0.3 percent increase compared with the corresponding quarter a year earlier.

The latest report also highlighted that net margin for the quarter stood at 4.12 percent and that return on equity reached 14.31 percent, underlining that the company is earning a mid-single-digit margin while achieving a double-digit return on shareholders capital in its most recent reporting period.

Guidance and consensus point to further EPS growth

Alongside the quarterly figures, CONMED Corporation has communicated full-year 2026 guidance for adjusted earnings per share in a range from 4.48 USD to 4.60 USD, with the midpoint of 4.54 USD representing a clear step up from the current run rate implied by the latest quarterly EPS of 1.38 USD.

For the same fiscal year 2026, market consensus compiled by analysts points to expected revenue of 1.362 billion USD, which would represent a modest 0.95 percent decline compared with the preceding year, while consensus EPS of 3.98 USD for 2026 would mark a substantial 163.58 percent increase versus the prior year.

These figures suggest that while top-line growth is expected to be broadly stable or slightly lower in 2026 compared with the previous year, profitability and earnings per share are projected to improve sharply as margin expansion and efficiency gains work through the income statement.

Surgical devices portfolio as growth driver

CONMED Corporation generates its revenue primarily from a portfolio of surgical devices and medical technologies used in minimally invasive procedures, orthopedics and general surgery, with a range of products that address both hospital and outpatient settings.

Within this portfolio, the companys arthroscopy and sports medicine solutions, as well as its energy and visualization systems, are central to its strategy of capturing procedure growth and shifting case volumes, offering healthcare providers equipment that supports efficient and reproducible clinical outcomes.

Stock valuation and investor perspective

Based on recent trading around the mid-40s USD per share and the companys guidance midpoint of 4.54 USD EPS for fiscal year 2026, CONMED Corporation stock is implicitly valued at a forward price to earnings multiple that reflects expectations for stronger profitability in the coming quarters.

Key data for CONMED Corporation

• Company: CONMED Corporation Inc.
• ISIN: US2074101013
• Ticker: CNMD
• Trading venue: NYSE
• Sector / Industry: Health Care / Medical Technology
• Index membership: Not a member of a major broad market index